Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shares were up 5.1% during trading on Monday . The company traded as high as $7.24 and last traded at $7.19. Approximately 846,659 shares were traded during trading, a decline of 33% from the average daily volume of 1,262,580 shares. The stock had previously closed at $6.84.

TTPH has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price for the company. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th. BMO Capital Markets reiterated an “outperform” rating and issued a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, July 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $11.13.

The stock’s market cap is $367.07 million. The stock’s 50-day moving average is $6.58 and its 200 day moving average is $7.30.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company had revenue of $1.59 million during the quarter, compared to the consensus estimate of $1.54 million. During the same quarter last year, the firm earned ($0.47) EPS. The business’s revenue for the quarter was up 28.2% on a year-over-year basis. On average, equities analysts predict that Tetraphase Pharmaceuticals, Inc. will post ($2.54) earnings per share for the current year.

In other news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the sale, the insider now owns 17,500 shares in the company, valued at $105,000. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 5.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of TTPH. Vanguard Group Inc. increased its position in Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after purchasing an additional 230,420 shares during the period. Dimensional Fund Advisors LP raised its holdings in Tetraphase Pharmaceuticals by 73.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock worth $7,853,000 after purchasing an additional 466,955 shares during the last quarter. Tekla Capital Management LLC raised its holdings in Tetraphase Pharmaceuticals by 422.2% during the 1st quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock worth $9,230,000 after purchasing an additional 812,000 shares during the last quarter. Northern Trust Corp raised its holdings in Tetraphase Pharmaceuticals by 4.8% during the 2nd quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock worth $6,323,000 after purchasing an additional 40,668 shares during the last quarter. Finally, Numeric Investors LLC raised its holdings in Tetraphase Pharmaceuticals by 1,363.3% during the 2nd quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock worth $5,379,000 after purchasing an additional 702,812 shares during the last quarter. Institutional investors and hedge funds own 41.73% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/02/tetraphase-pharmaceuticals-inc-ttph-trading-up-5-1.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.